thirty-three previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon-alpha-2c ( rifn-alpha-2c ) plus vincristine/melphalan/cyclophosphamide and prednisone ( vmcp ) or vmcp chemotherapy alone .
C0078398
vincristine/melphalan/cyclophosphamide
C0042679
vmcp